Compass Therapeutics, Inc. (CMPX) stock

CMPXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 7/30

$0.83−0.01 (-0.93%)

Close on Nov 11, 2026Market cap $149.51MP/E –Yield –

Compass Therapeutics profit margin

Profit margin (net margin) is net income as a percentage of revenue.

Compass Therapeutics's profit margin for the twelve months ending Dec 31, 2024 was -5808.8%. For fiscal 2024 it was -5808.8%.

Period	Period end	Value	Change (pts)
FY2024	Dec 31, 2024	-5808.8%	–

Change is against the same quarter a year earlier.

Period	Period end	Value	Change (pts)
Q2 FY2024	Jun 30, 2024	-1538.4%	–

Parsed from the XBRL in Compass Therapeutics's annual and quarterly filings with the SEC
Per-share figures adjusted for the 4-for-3 split on Aug 13, 2020
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is CMPX.

Advertisement
300 × 250

See a number that looks wrong?